Online inquiry

IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ5751MR)

This product GTTS-WQ5751MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 0
Species	Chimeric
RefSeq	NM_001346897.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	1956
UniProt ID	Q504U8

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5751MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ7205MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	FMC63 scFv-8A-F9Z CAR
GTTS-WQ15014MR	IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	SNDX-6352
GTTS-WQ9722MR	IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	JNJ-64407564
GTTS-WQ14574MR	IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	aCD1919
GTTS-WQ14703MR	IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	SEG101
GTTS-WQ15198MR	IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	TA-650
GTTS-WQ14185MR	IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	REGN-910
GTTS-WQ11389MR	IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	MEDI-575

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST